An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents

Trial Profile

An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Sodium benzoate (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors SyneuRx International (Taiwan) corp
  • Most Recent Events

    • 19 Mar 2017 Planned End Date changed from 1 Jun 2017 to 30 Jun 2019.
    • 19 Mar 2017 Planned primary completion date changed from 1 Jun 2016 to 13 Dec 2018.
    • 19 May 2015 Planned End Date changed from 1 Nov 2016 to 1 Jun 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top